TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06456515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib and Sintilimab in combination with electroacupuncture
Description: Regorafenib, take for 2 weeks and stop for 1 week; Sintilimab, intravenous, every 3 weeks; Electroacupuncture was performed 1 day before, on the day of, and on the 2nd day after each cycle of Sintilimab administration, and patients completed 3 treatments in week 1, followed by 1 treatment per week for 2 weeks, with 5 treatments per dosing cycle.
Study: NCT05441943

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymphovenous anastomosis
Description: Pre-operative planning prior to lymphovenous anastomosis using ICG lymphography and ultra high frequency ultrasound for mapping of applicable vessels.~During surgery, mapped vessels are freely dissected and anastomosed.
Study: NCT06353360

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tumor Treating Fields
Description: Tumor Treating Fields will be administered continuously with a planned ≥ 18 h per day, starting on the Day 1 of cycle 1 (C1D1), throughout the entire course of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab will be given 300 mg intravenously every 4 weeks beginning on Day 1 of Cycle 2 of adjuvant TMZ. The Tislelizumab treatment should be continued until confirmed PD, unacceptable toxicity, or finished Tislelizumab treatment for other reasons.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide (TMZ)
Description: The patients will carry out 6 cycles of TMZ adjuvant chemotherapy according to the instructions. The dosage of TMZ is 150-200 mg/(m2·d), daily for 5 days followed by 23 days without treatment, the treatment cycle is 28 days. The initial dose of cycle 1 is 150 mg/(m2·d), if patients do not experience TMZ chemotherapy toxicity, the dose should be increased to 200 mg/(m2·d) in subsequent treatment cycles. After 6 cycles of TMZ adjuvant chemotherapy, if the patients do not experience disease progression, it is recommended to continue TMZ adjuvant chemotherapy, or treated according to investigators' recommendations. The TMZ treatment should be continued until confirmed progressive disease (PD), unacceptable toxicity, or finished TMZ treatment for other reasons.
Study: NCT05963243

Intervention type: OTHER
Intervention: Ultrasound Scans
Description: Ultrasound scans collected by experts in ultrasound-guided regional anaesthesia.
Study: NCT05980195

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy
Description: Hyperbaric oxygen therapy for 30 times within 50 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard medical treatment
Description: Standard medical treatment consists of dual antiplatelet treatment (aspirin 100 mg per day for the entire follow-up, clopidogrel 75 per day mg, or ticagrelor 90 mg twice per day for 3 months after stenting).~Other Name: Dual antiplatelet therapy for 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard medical treatment
Description: Standard medical treatment consists of dual antiplatelet treatment (aspirin 100 mg per day for the entire follow-up, clopidogrel 75 per day mg, or ticagrelor 90 mg twice per day for 3 months after stenting).~Other Name: Dual antiplatelet therapy for 3 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Risk factor management
Description: Management of risk factors including hypertension, diabetes, lipoprotein metabolism disorder, smoking and exercise

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Risk factor management
Description: Management of risk factors including hypertension, diabetes, lipoprotein metabolism disorder, smoking and exercise
Study: NCT05792007

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biological sampling in patients
Description: blood and bone marrow samples from patients with Acute Leulemia.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Biological sampling in control patients
Description: blood and bone marrow samples from children undergoing orthopedic surgery exposing the bone marrow.(osteotomy of the pelvis).
Study: NCT04822818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEVA+SOC
Description: Bevacizumab : 7.5 mg / kg (with a maximum of 750 mg) on day 1 (D1) SOC : patients will receive the best of standard of care including corticosteroids, anticoagulant, antibiotics and tociluzimab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SOC
Description: patients will receive the best of standard of care including corticosteroids, anticoagulant, antibiotics and tociluzimab
Study: NCT06051955

Intervention type: OTHER
Group type: OTHER
Intervention: oral sodium sulfate
Description: All participants enrolled in this study will use Oral Sodium Sulfate as their bowel cleansing agent.
Study: NCT06037993

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ultra-micronized Palmitoylethanolamide (PEA)
Description: Palmitoylethanolamide (PEA) is an N-acylethanolamine (AE), produced on demand by different cell types as a response to actual or potential damage, proven to down-regulate central and peripheral activity of mast cells and non-neuronal cells (e.g., astrocytes, microglia) and to exert protective functions against glutamate neuro-toxicity, accounting for its naturally-occurring anti-inflammatory, analgesic, and anticonvulsant properties. Due to the shared pharmacodynamic properties, PEA is considered as the endogenous equivalent of Cannabidiol (CBD). A growing body of literature has confirmed the role of PEA in most neurobiological mechanisms underpinning several neuropsychiatric conditions both in clinical and preclinical settings. The effect of PEA over neuroinflammation and glutamate signaling may represent a promising biobehavioral mechanism underlying the clinical utility of its oral supplementation in CHR state.
Study: NCT06427863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ornidazole
Description: Patients will receive three consecutive enemas of ornidazole 0.5g+50ml saline through the TET tube, followed by WMT treatment once daily for a duration of 3 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive three consecutive enemas of placebo of equal volume through the TET tube, followed by WMT treatment once daily for a duration of 3 days
Study: NCT06258798

Intervention type: RADIATION
Intervention: Taking a dental X-ray
Description: Dental X-rays taken in patients with indications confirmed by a written referral.
Study: NCT04731753

Intervention type: DEVICE
Intervention: mechanical debridement
Description: The mechanical debridement is performed using the debridement pad Cutimed DebriClean. After the pad is moistened with wound-cleansing solution, the wound is cleaned using circular movements while applying gentle pressure.
Study: NCT05613296

Intervention type: DRUG
Intervention: Fostamatinib
Description: Patients with Chronic ITP, refractory to other treatment who received at least one dose of Fostamatinib outside clinical trials in Italy will be enrolled and observed for at least 6 months.
Study: NCT06035809

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMART
Description: A movement and body-based intervention in which participants are encouraged to explore the use of sensory equipment, which may help reduce symptoms related to psychological trauma/PTSD. Sensory equipment includes exercise balls, mini-trampoline, weighted blankets, and a hammock swing.
Study: NCT06154876

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cough assist device
Description: Cough assist device Cough Assist clears secretions from the lungs by gradually applying positive air pressure to the airway and then rapidly shifting to negative air pressure . The resulting high expiratory flow simulates a deep, natural cough.~Designed chest physical therapy Percussion, vibration, end expiratory pressure and bed mobility exercise.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cough assist device
Description: Cough assist device Cough Assist clears secretions from the lungs by gradually applying positive air pressure to the airway and then rapidly shifting to negative air pressure . The resulting high expiratory flow simulates a deep, natural cough.~Designed chest physical therapy Percussion, vibration, end expiratory pressure and bed mobility exercise.
Study: NCT05715437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine plus Normal Saline
Description: Effect of Bupivacain and ketamine and is superior to Bupivacaine and Normal Saline in terms of providing better pain control for 48 hours postoperatively after TKA.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacain and ketamine
Description: Effect of Bupivacain and ketamine and is superior to Bupivacaine and Normal Saline in terms of providing better pain control for 48 hours postoperatively after TKA.
Study: NCT06424015

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intralipid and heparin
Description: Intralipid (20%, 0.011ml/kg/min; Baxter, Healthcare, Deerfield, IL) and heparin (200 units prime, 0.2 unit/kg/min continuous) will be infused to induce acute insulin resistance
Study: NCT06525610

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Periprosthetic Fracture Knee Repaired CT Scans
Description: We will be assessing the use of weight-bearing CT, specifically its imaging, with RSA-like software, for analyzing fracture healing over time for a periprosthetic distal knee fracture.
Study: NCT04780802

Intervention type: PROCEDURE
Group type: OTHER
Intervention: The balloon catheter is placed at the various arterial feeders of the tumor
Description: use of a balloon catheter for providing balloon occlusion, in addition to the standard microcatheter for drug delivery, both catheters are to be placed in parallel through a single guide catheter. Only one arterial puncture wound is involved. The inflated balloon provides temporary occlusion of all arterial tumor feeders except for the one which is selectively catheterized with a microcatheter for delivery of the therapeutic agent. The therapeutic agent consists of Lipiodol mixed with a chemotherapeutic drug, it is delivered through the microcatheter under fluoroscopic control.
Study: NCT05960045

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Direct Milk antigen reintroduction
Description: Direct milk antigen re-introduction milk according to ESPGHAN guidelines

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Milk ladder
Description: B: Milk ladder according to the iMAP guideline which are 6 weeks of gradual reintroduction starting with baked milk not direct antigen
Study: NCT04911647

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ERCP using plastic stent
Description: Insertion of plastic stent (plastic stent with inner diameter 1.8mm or more) in the biliary obstruction will be performed using ERCP in the patients with the pancreatic cancer undergoing neoadjuvant therapy.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ERCP using metal stent
Description: Insertion of metal stent (full covered self-expandable metal stent) in the biliary obstruction will be performed using ERCP in the patients with the pancreatic cancer undergoing neoadjuvant therapy.
Study: NCT04695353

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Telemedicine: Virtual visits (videoconferences, texts)
Description: Patients will receive clinical care by using telemedicine (virtual visits)
Study: NCT06080074

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiohelp device (VA-ECMO)
Description: In children receiving the Cardiohelp device for severe heart failure, participants will be consented to a systematic data collection to describe the safety and effectiveness of the device in children.
Study: NCT06186908

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Saliva obtaining
Description: The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Tubes were stored at -80ºC until the day of analysis.
Study: NCT06433102

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visual perceptual training based on the lateral masking paradigm
Description: Visual perceptual training is a novel rehabilitation approach aimed at enhancing visual performance through practice of visual tasks. Patients received visual perceptual training based on the lateral masking paradigm every other day. Each training session consisted of 9 stages, totaling 900 trials, lasting 35 to 45 minutes. The stimuli consisted of a central Gabor patch with relatively low contrast positioned in the central fixation area, along with co-linear high-contrast Gabor patches distributed above and below the central stimulus. These stimuli were presented on a Liquid Crystal Display (LCD) monitor, with a training distance of 150 cm.
Study: NCT06186908

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Saliva obtaining
Description: The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Tubes were stored at -80ºC until the day of analysis.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Saliva obtaining
Description: The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Tubes were stored at -80ºC until the day of analysis.
Study: NCT06353633

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: formula
Description: The calories needed by the person are calculated and half of the calories are provided by formulas and the other half based on the elimination diet

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exclusion diet
Description: In this group, only the elimination diet is considered as an intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exclusion diet
Description: In this group, only the elimination diet is considered as an intervention
Study: NCT04709679

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MicroPulse TransScleral CycloPhotoCoagulation
Description: A laser power of 2000- 2500 mW, a laser duration time of 50 to 80 sec per hemifield and varying da number of sweeps per hemifield 3, 4 or 5 will be randomized between patients

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MicroPulse TransScleral CycloPhotoCoagulation
Description: A laser power of 2000- 2500 mW, a laser duration time of 50 to 80 sec per hemifield and varying da number of sweeps per hemifield 3, 4 or 5 will be randomized between patients

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MicroPulse TransScleral CycloPhotoCoagulation
Description: A laser power of 2000- 2500 mW, a laser duration time of 50 to 80 sec per hemifield and varying da number of sweeps per hemifield 3, 4 or 5 will be randomized between patients
Study: NCT05170477

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: apical patency
Description: In Gp A, apical patency will be maintained till obturation using electronic apex locator confirmed radiographically. Finally, Root canals will be obturated using cold lateral compaction technique. The molars will be permanently restored using composite resin restoration and will be scheduled for extra coronal restoration.
Study: NCT06424015

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline will be infused
Study: NCT03473769

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vital Signs at 2 Hours
Description: Patients vital signs assessed at 2 hours of arrival at ICU

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Confusion Assessment method for the ICU (CAM-ICU)
Description: patient must have altered mental status/fluctuating course and inattention, and either disorganized thinking or altered level of consciousness to be CAM positive; these features are determined by observing the patient during bedside cognitive testing.
Study: NCT06633471

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Two test formulations for the treatment of DED are being compared against the approved OTC formulation (Systane Ultra) and saline (placebo).
Description: Rain and Mist are the test formulations. Systane Ultra is an approved OTC formulation. Saline is the placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Two test formulations for the treatment of DED are being compared against the approved OTC formulation (Systane Ultra) and saline (placebo).
Description: Rain and Mist are the test formulations. Systane Ultra is an approved OTC formulation. Saline is the placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Two test formulations for the treatment of DED are being compared against the approved OTC formulation (Systane Ultra) and saline (placebo).
Description: Rain and Mist are the test formulations. Systane Ultra is an approved OTC formulation. Saline is the placebo.
Study: NCT05170477

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-apical surgery
Description: in Gp B apical patency will not be maintained. Finally, Root canals will be obturated using cold lateral compaction technique. The molars will be permanently restored using composite resin restoration and will be scheduled for extra coronal restoration
Study: NCT06633471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Two test formulations for the treatment of DED are being compared against the approved OTC formulation (Systane Ultra) and saline (placebo).
Description: Rain and Mist are the test formulations. Systane Ultra is an approved OTC formulation. Saline is the placebo.
Study: NCT05759936

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 500mg seaweed
Description: 4 week supplementation of 1 capsule per day of seaweed

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 week placebo supplement of 1 capsule per day
Study: NCT05592041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Banaba Leaf Extract
Description: a herbal extract in the form of Bigel
Study: NCT05084079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSII with formula-based initial insulin regimen
Description: Initial total daily insulin dose(TDD) for CSII was calculated with a formula :（estimate TDD-1(eTDD-1) = 0.35× body weight (kg) + 2.05× FPG (mmol/L) + 4.24×triglyceride(mmol/L) + 0.55× waist circumference (cm) - 49.1）, 42% of which was assigned as total basal dose and 58% as total premeal dose, with the pre-meal doses divided into 30:35:35 for breakfast, lunch and dinner.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CSII with weight-based initial insulin regimen
Description: TDD for CSII was started with 0.5 IU/kg, 50% of which was assigned as total basal dose and 50% as total premeal dose, and the total pre-meal dose was divided equally before each meal.
Study: NCT04786730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Centanafadine
Description: Doses of centanafadine will be taken once daily in the morning on Days 1 through 14. The fixed dose strengths will be administered according to body weight. Up to 12 subjects will be enrolled in the 9 to 12 years age cohorts (Cohorts 1 and 6), up to 8 subjects will be enrolled in each of the 6 to 8 years age cohorts (Cohorts 2 and 3), and up to 5 subjects will be enrolled in each of the 4 to 5 years age cohorts (Cohorts 4 and 5).
Study: NCT06177171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX727
Description: Given Orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX727
Description: Given Orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX727
Description: Given Orally
Study: NCT05722834

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SOAR intervention
Description: This program intervention will be over 6 weeks and participants will have two group sessions and individual sessions, all conducted by an asthma health coach over Zoom (or phone). The two Zoom group sessions will be recorded so that all the information from the conversations will be maintained and used for research purposes. Additionally, participants will keep track of asthma symptoms and complete surveys at specified time-points (the last one at 6 months after participation).~Primary care physicians will be sent emails regarding the self-management goals of their patients.
Study: NCT06457165

Intervention type: DEVICE
Intervention: Difficult Intubation
Description: Noted for each patient.

Intervention type: DEVICE
Intervention: Difficult Intubation
Description: Noted for each patient.
Study: NCT05023785

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cardio-oncology Rehabilitation (CORE)
Description: Exercise therapy, CVD risk factor management for the first 6 months (as per current standards in CR models) and behavioural support for the entire 2-year intervention period
Study: NCT06345261

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DiphenhydrAMINE 50 Mg/mL Injectable Solution
Description: injection of Diphenhydramine 50 Mg/mL

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: injection of saline
Study: NCT06138600

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabotegravir Injection [Apretude]
Description: White to slightly pink free flowing suspension suspension for injection contained in a brown coloured vial. Each vial is for single use and does not require dilution prior to administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir disoproxil fumarate / emtricitabine (or lamivudine)
Description: TDF/FTC is currently available as standard of care for PrEP in the public sector as per the department of health guidelines.